I'll just discuss this hypothetical a bit further. Again, very far fetched, but..... What if they are going to unblind formerly blinded interim analyses. What if that strained reading is the accurate reading? This would go back to the issue I had concerns with when I started investing in the company. In other words, what if they succeeded at early IAs but then had to continue the blind in order to have OS data with blinded integrity. That would be too much responsibility to place on LP's shoulders. So after my concerns, the trial did not even report IAs (hope it wasn't something I said or posted). We have no idea if they were conducted or if conducted what the recommendations were. Perhaps LP and LG didn't know what the recommendations were either (if they occurred). Their recent 8K made it sound like they might be as surprised by the "disclosure" as anyone else. Maybe just the steering committee and regulators knew the recommendations (if efficacy IAs occurred.) OK, enough grasping at straws. Who knows? Have a good weekend.
Market Data 
Markets 
